nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—AGTR2—uterus—polycystic ovary syndrome	0.0476	0.289	CbGeAlD
Tasosartan—AGTR2—endocrine gland—polycystic ovary syndrome	0.0362	0.22	CbGeAlD
Tasosartan—CYP3A4—urine—polycystic ovary syndrome	0.0179	0.109	CbGeAlD
Tasosartan—AGTR1—adrenal cortex—polycystic ovary syndrome	0.0129	0.0786	CbGeAlD
Tasosartan—AGTR1—pituitary gland—polycystic ovary syndrome	0.0105	0.0635	CbGeAlD
Tasosartan—AGTR1—adipose tissue—polycystic ovary syndrome	0.0104	0.0633	CbGeAlD
Tasosartan—AGTR1—adrenal gland—polycystic ovary syndrome	0.00935	0.0568	CbGeAlD
Tasosartan—AGTR1—vagina—polycystic ovary syndrome	0.00866	0.0526	CbGeAlD
Tasosartan—AGTR1—endocrine gland—polycystic ovary syndrome	0.0081	0.0492	CbGeAlD
Tasosartan—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00298	0.0181	CbGeAlD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00197	0.00236	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00193	0.00231	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00192	0.0023	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00191	0.00229	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00191	0.00229	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.00187	0.00223	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00184	0.00221	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00182	0.00217	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00181	0.00216	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.0018	0.00215	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00179	0.00215	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00179	0.00214	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00174	0.00208	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00174	0.00208	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00172	0.00206	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.00171	0.00205	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—GHRL—polycystic ovary syndrome	0.00169	0.00202	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00169	0.00202	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00168	0.00201	CbGpPWpGaD
Tasosartan—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—polycystic ovary syndrome	0.00168	0.00201	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00165	0.00197	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00154	0.00184	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00154	0.00184	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—polycystic ovary syndrome	0.00153	0.00184	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.00153	0.00183	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.0015	0.0018	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.0015	0.00179	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FSHR—polycystic ovary syndrome	0.0014	0.00168	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—CYP1A1—polycystic ovary syndrome	0.0014	0.00167	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00139	0.00167	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00138	0.00165	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—POMC—polycystic ovary syndrome	0.00137	0.00164	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00136	0.00163	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00132	0.00159	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00132	0.00157	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00131	0.00157	CbGpPWpGaD
Tasosartan—CYP3A4—Xenobiotics—CYP1A1—polycystic ovary syndrome	0.00128	0.00154	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.00128	0.00153	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00128	0.00153	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00126	0.00151	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00126	0.00151	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FST—polycystic ovary syndrome	0.00125	0.00149	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.00124	0.00148	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—CYP1A1—polycystic ovary syndrome	0.00123	0.00148	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00123	0.00147	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00123	0.00147	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.00123	0.00147	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00123	0.00147	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LHB—polycystic ovary syndrome	0.00122	0.00146	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.00119	0.00142	CbGpPWpGaD
Tasosartan—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—polycystic ovary syndrome	0.00119	0.00142	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00117	0.0014	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00116	0.00139	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00116	0.00139	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00115	0.00138	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.00115	0.00138	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00114	0.00137	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SCT—polycystic ovary syndrome	0.00114	0.00137	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00113	0.00136	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.00113	0.00135	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—VEGFA—polycystic ovary syndrome	0.00111	0.00133	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.0011	0.00131	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.00109	0.0013	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00109	0.0013	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FGF18—polycystic ovary syndrome	0.00107	0.00128	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RBP4—polycystic ovary syndrome	0.00106	0.00127	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00105	0.00126	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00105	0.00126	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00105	0.00126	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.00104	0.00125	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00103	0.00123	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00099	0.00119	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.000986	0.00118	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000976	0.00117	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.000958	0.00115	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.000939	0.00112	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—INSR—polycystic ovary syndrome	0.000934	0.00112	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.000933	0.00112	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.000931	0.00112	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—polycystic ovary syndrome	0.000899	0.00108	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000887	0.00106	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—polycystic ovary syndrome	0.000887	0.00106	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.000874	0.00105	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000873	0.00105	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PGR—polycystic ovary syndrome	0.000864	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.000864	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000854	0.00102	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00085	0.00102	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.000847	0.00101	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—AKR1C2—polycystic ovary syndrome	0.000842	0.00101	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—polycystic ovary syndrome	0.000836	0.001	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—polycystic ovary syndrome	0.000825	0.000987	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP19A1—polycystic ovary syndrome	0.000818	0.000979	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000804	0.000962	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000804	0.000962	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.000777	0.000931	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000774	0.000927	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.000772	0.000924	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000767	0.000918	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.000748	0.000896	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000748	0.000895	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NPB—polycystic ovary syndrome	0.000746	0.000893	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000744	0.000891	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.000739	0.000885	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.000729	0.000872	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.000723	0.000865	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.000715	0.000856	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000708	0.000847	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000706	0.000845	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000703	0.000842	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PRL—polycystic ovary syndrome	0.000701	0.000839	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.000693	0.000829	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000679	0.000813	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.000677	0.000811	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000676	0.000809	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000675	0.000808	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000671	0.000804	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000665	0.000796	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000663	0.000794	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.000661	0.000792	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000661	0.000791	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP1A1—polycystic ovary syndrome	0.000659	0.000789	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000656	0.000786	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.000653	0.000781	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.000635	0.00076	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000629	0.000753	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000623	0.000746	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000623	0.000746	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000617	0.000738	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.0006	0.000719	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000588	0.000703	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000586	0.000702	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000583	0.000697	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000577	0.00069	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000566	0.000677	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00055	0.000659	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000536	0.000642	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000536	0.000642	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000533	0.000638	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000526	0.00063	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000501	0.000599	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000494	0.000591	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000488	0.000584	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LEP—polycystic ovary syndrome	0.000483	0.000579	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000468	0.000561	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000456	0.000546	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000446	0.000534	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000443	0.000531	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.000437	0.000523	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.000432	0.000517	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000431	0.000516	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.000431	0.000516	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000429	0.000513	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000417	0.000499	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—POMC—polycystic ovary syndrome	0.000415	0.000497	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—INS—polycystic ovary syndrome	0.000413	0.000494	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FST—polycystic ovary syndrome	0.000406	0.000486	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000404	0.000484	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000401	0.000481	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000399	0.000478	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000399	0.000478	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.000397	0.000476	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000397	0.000475	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000388	0.000464	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.000387	0.000463	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.000382	0.000457	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000379	0.000454	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000375	0.000449	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000375	0.000449	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000372	0.000445	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000367	0.000439	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.00036	0.000432	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.00036	0.000431	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.000355	0.000425	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000355	0.000424	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000348	0.000417	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000346	0.000414	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000344	0.000412	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.00034	0.000407	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000323	0.000386	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.000322	0.000386	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000318	0.000381	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000306	0.000366	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000304	0.000364	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000289	0.000346	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000285	0.000341	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000285	0.000341	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000282	0.000337	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.000281	0.000336	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000262	0.000313	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000262	0.000313	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000261	0.000312	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000252	0.000302	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.00025	0.000299	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000244	0.000292	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000242	0.00029	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000231	0.000276	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.00023	0.000275	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000229	0.000274	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000228	0.000274	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000226	0.000271	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.00022	0.000264	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000217	0.000259	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	0.000202	0.000242	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000201	0.000241	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000191	0.000229	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000188	0.000225	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	0.000185	0.000221	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	0.000185	0.000221	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6—polycystic ovary syndrome	0.00018	0.000216	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	0.000172	0.000205	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	0.000171	0.000205	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000161	0.000193	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LEP—polycystic ovary syndrome	0.000158	0.000189	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	0.000146	0.000175	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	0.000146	0.000175	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000141	0.000168	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000135	0.000162	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—INS—polycystic ovary syndrome	0.000135	0.000161	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.00013	0.000156	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.00013	0.000156	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000124	0.000148	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	0.000122	0.000146	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	0.000116	0.000139	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	0.000111	0.000132	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6—polycystic ovary syndrome	9.95e-05	0.000119	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	9.86e-05	0.000118	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	9.41e-05	0.000113	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	8.58e-05	0.000103	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.5e-05	0.000102	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	8.38e-05	0.0001	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	8.12e-05	9.72e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	7.47e-05	8.94e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	7.24e-05	8.66e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	6.98e-05	8.35e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	6.7e-05	8.02e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	6.62e-05	7.92e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	6.25e-05	7.48e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	6.15e-05	7.37e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6—polycystic ovary syndrome	5.88e-05	7.04e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TH—polycystic ovary syndrome	5.32e-05	6.37e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	5.18e-05	6.2e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	4.87e-05	5.83e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	4.35e-05	5.2e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	4.14e-05	4.96e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	3.93e-05	4.7e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	3.66e-05	4.38e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	2.97e-05	3.55e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	2.93e-05	3.5e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—INS—polycystic ovary syndrome	2.91e-05	3.48e-05	CbGpPWpGaD
